BIIB - Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease | Benzinga
Biogen Inc. (NASDAQ: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in mild Alzheimer's disease (AD).
The data showed favorable trends on multiple exploratory endpoints of cognition and activities of daily living in AD, building upon prior results. These preliminary results showed a reduction of tau protein in the cerebral spinal fluid and tau positron emission tomography (PET) across brain regions.
Biogen's late-breaking results were presented at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) meeting held in Boston, MA from October 24 to 27.
In December 2019, Biogen exercised a license option and obtained a ...